1. Hospital Clínic, Hematology Department, Institut d'Investigació Biomédica August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;
3. The Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre d'Investigations Cliniques and Department of Clinical Pharmacology, Université Paris Diderot, Paris, France;
4. Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany;
5. Novartis Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ;
6. Oncology Global Development, Novartis Pharma AG, Basel, Switzerland;
7. Clinical Development, Incyte Corporation, Wilmington, DE;
8. Department of Hematology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy;
9. Department of Hematology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy;
10. Center for the Study of Myelofibrosis, Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy;
11. Department of Haematology, Guy’s and St. Thomas’ National Health Service Foundation Trust, London, United Kingdom;
12. Hematology Unit, Cliniques Universitaires Saint-Luc and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; and
13. Department of Internal Medicine, Medical University of Vienna, Vienna, Austria